MRNA-1644 is under clinical development by Moderna and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MRNA-1644’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 19 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MRNA-1644 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
mRNA-1644 is under development for the prevention of HIV. The therapeutic candidate constitutes a protein nanoparticle which acts by targeting B cells. It is administered through intramuscular route. It is developed based on mRNA vaccine platform.
Moderna operates as a developer of messenger RNA therapeutics. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Quick View MRNA-1644 LOA Data
|Highest Development Stage|